![]() |
市场调查报告书
商品编码
1346714
苯丙胺酸市场:现况分析与预测(2022-2030)Phenylalanine Market: Current Analysis and Forecast (2022-2030) |
由于大豆和豌豆等许多植物蛋白来源中苯丙胺酸含量较高,苯丙胺酸市场在预测期内(2023-2030年)复合年增长率为3.8%,预计增长强劲。 此外,随着精神疾病盛行率的上升,对含有苯丙胺酸或其衍生物的补充剂的需求增加,预计该市场在未来几年将扩大。 根据美国国家慢性病预防与健康促进中心的数据,到 2023 年,美国将有超过五分之一的成年人患有精神疾病。 现在或一生中的某个阶段,超过五分之一的年轻人(13 至 18 岁)都受到严重且令人衰弱的精神疾病的影响。
市场依类型分为 L-苯丙胺酸、D-苯丙胺酸和 DL-苯丙胺酸。 其中,医药和食品业对L-苯丙胺酸的需求不断增加,并在2022年占据市场主导地位。 此外,人们对 L-苯丙胺酸益处的认识不断提高也促进了市场的成长。
根据应用,市场分为忧郁症、注意力不足过动症、巴金森氏症、慢性疼痛、白斑症等。 其中,忧郁症预计在预测期(2023-2030年)将以较大的复合年增长率成长。 虽然苯丙胺酸在多巴胺的产生中发挥重要作用,有助于缓解忧郁症,但它也与越来越多的忧郁症和精神疾病有关。 根据人口健康部门的数据,到 2023 年 4 月,美国大约每 25 名成年人中就有 1 人患有严重精神疾病,如精神分裂症、躁郁症或重度忧郁症。
依最终用户划分,市场分为食品和饮料、营养补充品、药品等。 预计食品和饮料类别在预测期内(2023-2030 年)将以显着的复合年增长率成长。 这是因为它广泛用于生产各种食品和饮料产品。 常用作增味剂、营养源及防腐剂。 它广泛用于食品工业製造阿斯巴甜和三氯蔗糖等人工甜味剂。
为了更了解苯丙胺类产业的市场介绍,将市场分为北美(美国、加拿大、北美其他地区)、欧洲(德国、英国、法国、义大利、西班牙、欧洲其他地区)、亚太地区(中国、日本、印度、韩国等亚太地区国家)及全球其他国家。 由于对富含蛋白质的食品的需求不断增加以及糖尿病、心臟病和癌症等慢性疾病的患病率不断增加,2022年的苯丙氨酸市场由北美主导,这往往与不健康的饮食习惯和缺乏运动有关。 根据 2021 年 IDF 糖尿病图谱,20 岁至 79 岁之间的成年人中有 10.5% 患有糖尿病,其中近一半人不知道自己患有糖尿病。 根据 IDF 预测,到 2045 年,约有 7.83 亿人(即八分之一的人)患有糖尿病,增幅为 46%。 需要苯丙胺酸来製造治疗这些疾病的药物,随着患有慢性病的人数持续成长,苯丙胺酸的市场也将持续成长。
The body uses phenylalanine which is an essential amino acid, to make proteins and other compounds. It is also a precursor to the neurotransmitters dopamine, norepinephrine, and serotonin involved in regulating mood, motivation, and other aspects of mental health. The surge in demand for phenylalanine and its subordinates is driven by various elements, including the development of the food and drink industry, the rising prominence of plant-based diets with fewer calories, and the rising predominance of emotional well-being problems such as anxiety and depression.
The Phenylalanine Market is expected to grow at a strong CAGR of 3.8% during the forecast period (2023-2030) owing to the rising demand for phenylalanine, as many plant-based protein sources such as soybeans and peas contain high levels of phenylalanine. Adding to this, the market is anticipated to expand in the forecast years due to the rising prevalence of mental health disorders has led to a growing demand for supplements that contain phenylalanine or its derivatives. As per the National Center for Chronic Disease Prevention and Health Promotion, in 2023, over 1 in 5 adults in the United States suffer from mental illness. A seriously debilitating mental illness has affected more than one in five young people (ages 13 to 18) either now or at some point in their lives.
Based on the type, the market is segmented into L-phenylalanine, D-phenylalanine, and DL-phenylalanine. Amongst these, the L-phenylalanine segment dominated the market in 2022 due to the expanding requirement for L-phenylalanine in the pharmaceutical and food industries. Also, the rising awareness of the advantages of L-phenylalanine is also contributing to the growth of the market.
By application, the market is segmented into depression, attention deficit disorder, Parkinson's disease, chronic pain, vitiligo, and others. Among these, depression is expected to grow with a significant CAGR during the forecast period (2023-2030). The rising number of depression and mental health disorders while phenylalanine supports depression relief because it plays a crucial role in the production of dopamine. According to the Division of Population Health, in April 2023, approximately one in every 25 adults in the United States, adults lives with a serious mental illness, such as schizophrenia, bipolar disorder, or major depression.
On the basis of end-users, the market is segmented into food and beverage, dietary supplements, pharmaceuticals, and others. The food and beverage category is expected to grow at a substantial CAGR during the forecasted period (2023-2030). This is because of widely used in the production of a wide range of food and beverage products. It is commonly used as a flavor enhancer, a source of nutrition, and a preservative. In the food industry, this is extensively used in the production of artificial sweeteners, such as aspartame and sucralose
For a better understanding of the market adoption of the phenylalanine industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, and Rest of Asia-Pacific), Rest of World. North America dominated the phenylalanine market in 2022 due to the increasing demand for protein-rich foods, and the increasing prevalence of chronic diseases such as diabetes, heart disease, and cancer that are becoming more prevalent and are frequently linked to unhealthy eating habits and inactivity. According to the IDF Diabetes Atlas in 2021, 10.5% of adults aged 20 to 79 have diabetes, and nearly half of them are unaware that they have the condition. According to IDF projections, approximately 783 million adults-or 1 in 8-will have diabetes by 2045, an increase of 46%. The production of medicines to treat these conditions necessitates phenylalanine, and as the number of people living with chronic conditions continues to rise the market for phenylalanine.
Some of the major players operating in the market include: Ajinomoto Co., Inc.; DAESANG; Livzon; KYOWA HAKKO BIO CO., LTD.; Amazing Nutrition; AMINO GmbH; Wuxi Jinghai Amino Acid Co., Ltd.; Shijiazhuang Jirong Pharmaceutical Co., Ltd.; Shijiazhuang Haitian Amino Acid Co., Ltd.; NOW Foods.